Zomedica (ZOM) Stock Price, News & Analysis

Company Overview

Zomedica Corp. (NYSEAMERICAN:ZOM) is a veterinary health company focused on developing and commercializing products and services for companion-animal veterinarians. The company’s offerings are designed to support the diagnosis, treatment and monitoring of dogs, cats and other small animals in clinical settings.

Zomedica’s product portfolio includes the Truforma point-of-care diagnostic platform, which uses immunoassay technology to help veterinary practices evaluate certain endocrine and adrenal conditions. The company also offers veterinary medical devices and therapeutic technologies, including PulseVet extracorporeal shock-wave therapy systems and products from Assisi Animal Health that use pulsed electromagnetic field technology.

Founded in 2015, Zomedica has expanded its business through internal product development and acquisitions of veterinary technology companies. The company is headquartered in Ann Arbor, Michigan, and primarily serves the companion-animal veterinary market through direct and distribution-based sales channels. Its products are intended to help veterinary practices improve clinical decision-making and broaden the services available to pet owners.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 790,936 shs
• Average Volume: 4.72 million shs
• Market Capitalization: $95.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/07/2024
• Today: 10/13/2026
• Investor update: 10/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSEAMERICAN:ZOM
• CIK: 1684144
• Web: www.zomedica.com
• Phone: 734-369-2555
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.53 million
• Net Margins: -232.88%
• Pretax Margin: -232.24%
• Return on Equity: -12.47%
• Return on Assets: -11.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.82
• Quick Ratio: 10.15

Sales & Book Value

• Annual Sales: $25.19 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.24 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 979,950,000
• Free Float: 938,890,000
• Market Cap: $95.35 million
• Optionable: Not Optionable
• Beta: 1.03